



## Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference

February 9, 2022

ZUG, Switzerland, Feb. 09, 2022 (GLOBE NEWSWIRE) -- [Pharvaris](#) (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in a fireside chat at the 11<sup>th</sup> Annual SVB Leerink Global Healthcare Conference taking place virtually from February 14–18, 2022.

The fireside chat will take place on Wednesday, February 16 at 4:40 PM CEST (10:40 AM EST). A live audio webcast will be available on the Investors section of the Pharvaris website at: <https://ir.pharvaris.com/news-events/events-presentations>. A replay will be available on Pharvaris' website for 30 days following the presentation.

### About Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit <https://pharvaris.com/>.

### For more information:

#### Pharvaris

Maryann Cimino  
Director of Corporate Relations  
+1-617-710-7305  
[maryann.cimino@pharvaris.com](mailto:maryann.cimino@pharvaris.com)

#### Investor Contact

Sarah McCabe  
Stern Investor Relations, Inc.  
+1-212-362-1200  
[sarah.mccabe@sternir.com](mailto:sarah.mccabe@sternir.com)

#### Media Contact

Maggie Beller  
Russo Partners, LLC  
+1-646-942-5631  
[maggie.beller@russopartnersllc.com](mailto:maggie.beller@russopartnersllc.com)